Expert Interview
Discussing the 2020 ASH Presentation "Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial"
Ticker(s): EQInstitution: Rochester Skin Lymphoma Medical Group
- Director of the RSLM Group - clinic which focuses solely on patients with skin lymphoma and is a top recruiting international site for clinical trials in these cancers.
- Manages hundreds of patients with skin lymphoma; has a laboratory at the Rochester General Hospital Research Institute, where he studies the underlying mechanism of skin cancers.
- Recently funded by the NIH and has been on many NIH review committees; frequent speaker in the field of lymphoma and skin cancer.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
